InternationalUSRemember you can easily switch between MIP US and MIP International at any time

A quiet year from the EU’s courts in design cases


While 2016 was a quiet year for design decisions in the Court of Justice, 2017 looks to be a cracker year of important cases. In the first of two articles, David Stone looks back at the year that was. Next month, he looks forward to some of the key decisions expected in 2017

2016 was a quiet year for design decisions from the General Court and Court of Justice in Luxembourg. Unlike the apparently never-ending flurry of trade mark cases, significantly fewer design-related decisions are appealed from the EUIPO to the General Court,...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

"Call it something with the word Virgin" maybe??? https://t.co/X7J2iiMYtZ

Mar 29 2017 04:57 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @HouseJudiciary: ✅ #BREAKING: @HouseJudiciary approves #HR1695- Register of Copyrights Selection & Accountability Act. 1st step to moder…

Mar 29 2017 04:37 ·  reply ·  retweet ·  favourite
ManagingIP profile

SCOTUS revisits patent venue in TC Heartland v Kraft arguments - analysis https://t.co/u8u7RmhQ7J https://t.co/bqESUSa7Vq

Mar 29 2017 04:36 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements